FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Angela Howes

Research Profile

Disorders

Breast Neoplasms

Chemicals & Drugs

Physiology

Living Beings

Co-author Network

Publications

TOP 3
Lesley-Ann Martin; Julia E Head; Sunil Pancholi; Janine Salter; Emma Quinn; Simone Detre; Stan Kaye; Angela Howes; Mitch Dowsett; Stephen R D Johnston
The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.
Stephen R D Johnston; Tamas Hickish; Paul Ellis; Stephen Houston; Lloyd R Kelland; Mitch Dowsett; Janine Salter; Bart Michiels; Juan Jose Perez-Ruixo; Peter Palmer; Angela Howes
Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.
Catherine Harper-Wynne; Nigel Sacks; Karyn Shenton; Fiona A MacNeill; Paul Sauven; Ian J Laidlaw; Zen Rayter; Stephanie Miall; Angela Howes; Janine Salter; Margaret Hills; Frances M Lowe; Roger A'Hern; Nazar Nasiri; Deborah Doody; Jhangir Iqbal; Mitchell Dowsett
Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Angela Howes (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Lesley-Ann Martin; Julia E Head; Sunil Pancholi; Janine Salter; Emma Quinn; Simone Detre; Stan Kaye; Angela Howes; Mitch Dowsett; Stephen R D Johnston
The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.
Molecular cancer therapeutics 2007;6(9):2458-67.
2003: Stephen R D Johnston; Tamas Hickish; Paul Ellis; Stephen Houston; Lloyd R Kelland; Mitch Dowsett; Janine Salter; Bart Michiels; Juan Jose Perez-Ruixo; Peter Palmer; Angela Howes
Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2492-9.
2002: Catherine Harper-Wynne; Nigel Sacks; Karyn Shenton; Fiona A MacNeill; Paul Sauven; Ian J Laidlaw; Zen Rayter; Stephanie Miall; Angela Howes; Janine Salter; Margaret Hills; Frances M Lowe; Roger A'Hern; Nazar Nasiri; Deborah Doody; Jhangir Iqbal; Mitchell Dowsett
Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(4):1026-35.
2001: Lloyd R Kelland; V Smith; Melanie Valenti; Lisa Patterson; Paul A Clarke; S Detre; D End; Angela Howes; Mitch Dowsett; Paul Workman; Stephen R D Johnston
Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(11):3544-50.
1999: Mitch Dowsett; Deborah Doody; S Miall; Angela Howes; J English; R C Coombes
Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.
Breast cancer research and treatment 1999;56(1):25-34.